New findings from the PRECISION study, published in @ESMO_Open, highlight how our Guardant360® Liquid & Guardant Reveal® tests can provide complementary insights for patients undergoing surgery for #ColorectalCancer metastases.
Combining pretreatment genomic profiling and MRD testing identified 3 distinct risk groups, with estimated 2-year recurrence-free survival ranging from 78% to 9%.
These findings deepen our understanding of recurrence risk & could help inform the development of more personalized treatment strategies.
Details: bit.ly/4zxgSmi
Combining pretreatment genomic profiling and MRD testing identified 3 distinct risk groups, with estimated 2-year recurrence-free survival ranging from 78% to 9%.
These findings deepen our understanding of recurrence risk & could help inform the development of more personalized treatment strategies.
Details: bit.ly/4zxgSmi
0:55
